The Role of Central Serotonergic and Adrenergic Systems in the Effectiveness of DNIC (Diffuse Noxious Inhibitory Control

The recruitment status of this study is unknown because the information has not been verified recently.

Verified February 2008 by Rambam Health Care Campus. Recruitment status was Active, not recruiting

First Received on April 15, 2008. Last Updated on April 16, 2008 History of Changes

Sponsor:	Rambam Health Care Campus
Information provided by:	Rambam Health Care Campus
ClinicalTrials.gov Identifier:	NCT00660751

Purpose

The role of central serotonergic and adrenergic systems in the effectiveness of DNIC (Diffuse Noxious Inhibitory Control) will be tested before and after taking Duloxetine and Placebo in a double blind study.

Condition	Intervention
Healthy	Drug: Duloxetine

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Single Group Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Basic Science
Official Title:	The Role of Central Serotonergic and Adrenergic Systems in the Effectiveness of DNIC (Diffuse Noxious Inhibitory Control

Resource links provided by NLM:

Drug Information available for: Duloxetine Duloxetine hydrochloride

U.S. FDA Resources

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:

level of DNIC [ Time Frame: 1 week ] [ Designated as safety issue: No ]

Estimated Enrollment:	100
Study Start Date:	August 2007
Estimated Primary Completion Date:	August 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: 1	Drug: Duloxetine SNRIs
Placebo Comparator: 2	Drug: Duloxetine SNRIs

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Healthy volunteers
age 18-80
no chronic disease

Exclusion Criteria:

Subjects who suffer from chronic pain / pain syndrome
use of anti-depressant or anti-psychotic drugs
food/ drugs sensitivity
breast feeding

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00660751

Locations

Israel
Rambam Health Care Campus
Haifa, Israel, 31096

Sponsors and Collaborators

Rambam Health Care Campus

Investigators

Principal Investigator:

Prof. David Yarnitsky

More Information

No publications provided

Responsible Party:	Prof. David Yarnitsky/ Head of Neurology Department, Rambam Health Care Campus
ClinicalTrials.gov Identifier:	NCT00660751 History of Changes
Other Study ID Numbers:	DNIC01CTIL
Study First Received:	April 15, 2008
Last Updated:	April 16, 2008
Health Authority:	Israel: Ministry of Health

Keywords provided by Rambam Health Care Campus:

Physiology of Serotonergic and Adrenergic systems

Additional relevant MeSH terms:

Adrenergic Agents
Duloxetine
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors

Serotonin Agents
Adrenergic Uptake Inhibitors
Dopamine Uptake Inhibitors
Dopamine Agents
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 09, 2012